Cardiomatics

APRIL 5, 2024

Sinus tachycardia – sinus rhythm above 100 bpm is a sinus tachycardia. Ventricular tachycardia – more than 7 consecutive complexes originating from ventricles at a rate of > 100 bpm. Supraventricular tachycardia – more than 7 consecutive complexes of supraventricular beats at a rate of > 100 bpm.

Arrhythmia 92

Arrhythmia Tachycardia Bradycardia Electrocardiogram 92

DAIC

MAY 17, 2024

Laurent Fiorina, Cardiovascular Institute Paris-Sud (ICPS) and medical advisor for Philips, said: “Our main focus is developing new AI models to detect cardiovascular conditions or predict future cardiac events like atrial fibrillation, ventricular tachycardia, and now, severe bradyarrhythmia.”

Heart Rhythm 52

Heart Rhythm Technology Arrhythmia Outcomes 52

Wellnest

JUNE 19, 2023

By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. The advances lead to better patient care with accurate diagnosis and treatment. Alternatively, it also helps enhance arrhythmia management with coronary artery disease.

Technology 52

Technology Cardiac Arrest Innovation Coronary Artery Disease 52

CardiacWire

DECEMBER 3, 2023

Jimenez and Ali co-founded AccurKardia in 2019 with a vision for unlocking the value of the ECG signal, and the company currently markets one of the few FDA-cleared solutions for automated ECG interpretation and arrhythmia detection. Here’s the rest of their story and vision for ECG automation.

Arrhythmia 52

Arrhythmia Atrial Flutter Reimbursement Atrial Fibrillation 52

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

Dr. Smith's ECG Blog

APRIL 8, 2015

Check : [vitals, SOB, Chest Pain, Ultrasound] If the patient has Abdominal Pain, Chest Pain, Dyspnea or Hypoxemia, Headache, Hypotension , then these should be considered the primary chief complaint (not syncope). The most recent and probably best study is this: Canadian Syncope Arrhythmia Risk Score. Thiruganasambandamoorthy, V.,

Arrhythmia 52

Arrhythmia Outcomes Risk Factors Chest Pain 52

Cardiometabolic Health Congress

JANUARY 2, 2025

Landiolol Approval Date: November 22, 2024 Indication: Approved for the treatment of supraventricular tachycardia (SVT). Studies on Supraventricular Tachycardia : 5 studies , a total of 317 adults. Heart rate decrease criteria: >20% decrease, HR <100 bpm, or arrhythmia cessation. Placebo: 0%-11%. Placebo: 1%.

Coronary Artery Disease 52

Coronary Artery Disease Stent Stents Innovation 52